Influenza Treatment Market Research, 2026
The global influenza treatment market size accounted for $861.50 million in 2018, and is expected to reach $1,225.20 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Influenza is commonly known as flu and is a contagious respiratory infection, which is caused by influenza viruses. Furthermore, the virus is classified into Type A, B, C, and D. The most common types of influenza virus responsible for seasonal flu each year are Type A and B. Moreover, these viruses attack respiratory system of an individual and are transmitted to other individual by direct contact or inhalation of virus laden aerosols. The major symptoms of the disease include sore throat, fatigue, muscle ache, vomiting, and diarrhea. In addition, it can worsen long-term medical conditions like congestive heart failure, asthma, or diabetes which, in turn, can lead to serious complications. Therefore, influenza infections are treated in time using various types of anti-viral drugs such as Peramivir and Zanamivir.
Market Dynamics
The major factor that contribute to the growth of the influenza treatment market include rise in incidences of influenza across the globe. Furthermore, other factors such as surge in healthcare expenditure, and rise in R&D investments related to anti-viral drugs further boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza. Furthermore, Xofluza is the first new flu medicine with a novel proposed mechanism of action. Therefore, this leads to availability of better treatment option for the patients. However, adoption of influenza vaccines hampers the growth of the influenza treatment market. Conversely, high growth potential exhibited by developing economies such as India and China having a large population base and notable epidemiology of influenza infection is expected to offer lucrative opportunities for the market during the forecast period.
Segments Overview
The influenza treatment market size is studied on the basis of product type, distribution channel, and region to provide a detailed assessment. On the basis of product type, it is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. By distribution channel, it is bifurcated into retail pharmacy, hospital pharmacy, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
By Product
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The others segment acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit fastest growth during the forecast period. The growth of this segment is attributable to surge in prevalence of influenza virus infection across the globe. Furthermore, rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By Product Type
Other products is projected as one of the most lucrative segment.
By Distribution Channel
By distribution channel, the influenza treatment market is divided into retail pharmacy, hospital pharmacy, and others. The retail pharmacy segment occupied the largest market share in 2018, owing to factors such as rise in number of retail pharmacies across the globe. In addition, other factors such as rise in awareness related to use of influenza drugs is another major factor that contributes to the growth of the market. The other factors which boost the growth of the market include surge in the number of retail pharmacies across the globe which lead to easy availability of influenza drugs. On the contrary, the others segment is expected to witness the fastest growth rate during the forecast period due to surge in use of internet across the globe, which allows consumers to buy drugs online.
By End User
Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
By Region
By region, North America accounted for the major influenza treatment market share in 2018, and is expected to continue this trend, owing to easy availability of influenza treatment. Moreover, surge in incidences of influenza infection is another major reason that contributes to the growth of this market. Moreover, surge in the awareness towards early diagnosis of the medical condition for better treatment is another major factor that contributes to the growth of the market. However, Asia-Pacific is estimated to register the fastest growth rate during the forecast period, owing to increase in awareness regarding the use of influenza drugs for the treatment of infection.
Moreover, increase in healthcare expenditure and surge in awards related to use of influenza treatment is another major factor that boosts the growth of the influenza treatment market. In addition, presence of key players in these regions also fuels the growth of the influenza treatment in Asia-Pacific. In addition, the constantly evolving life science industry in Asia-Pacific drives the growth of the market in developing economies such as India, China, and Malaysia.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 5.60% during 2019-2026.
The global influenza treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include AstraZeneca Plc, BioCryst Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Mylan N.V, Natco Pharma Limited, Novartis AG, Sanofi, and Teva Pharmaceutical Industries Limited.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis along with the global influenza treatment market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The influenza treatment market forecast is studied from 2018 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the influenza treatment industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the influenza treatment market.
Influenza Treatment Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | NATCO Pharma Limited, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche AG, AstraZeneca Plc, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, BioCryst Pharmaceuticals, Inc., NOVARTIS AG, GlaxoSmithKline Plc, MYLAN N.V, SANOFI |
Analyst Review
Influenza is defined as a viral infection which affects the respiratory system. The early symptoms of the disease include high fever, muscle pain, headache, and others. Furthermore, the infection is air-borne and is highly contagious. The treatment of the infection is achieved through administration of various anti-viral drugs such as Peramivir, Zanamivir, and Oseltamivir and others.
The utilization of influenza drugs has witnessed a significant growth, owing to surge in incidences of influenza across the globe. The other factors that propel the utilization of different influenza treatments include surge in healthcare expenditure and rise in R&D investments related to anti-viral drugs. Conversely, surge in adoption of influenza vaccines is a factor that restricts the growth of the market. However, high market potential due to rise in awareness related to availability and use of influenza treatment options offered by in developing economies is expected to present lucrative opportunities for the key players during the forecast period..
The total market value of influenza treatment market is $ 861.50 million in 2018.
The forecast period for influenza treatment market is 2019 to 2026.
The market value of influenza treatment market in 2019 is $ 900.30 million.
The base year is 2018 in influenza treatment market.
Top companies such as, AstraZeneca Plc, F. Hoffmann-La Roche AG., GlaxoSmithKline Plc, Mylan N.V, and Daiichi Sankyo Company, Limite held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
Other influenza treatments segment is the most influencing segment surge in the prevalence of the influenza virus infection across the globe. Furthermore, the surge in the awareness related to early diagnosis of the infection for better treatment is another major reason that contribute to the growth of the market.
The major factor that fuels the growth of the global influenza treatment market includes rise in R&D investments for discovery of new drug molecules. Therefore, this leads to availability of better treatment option for the patients.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.6%. Presence of a large patient base coupled with surge in awareness relate to early diagnosis of the medical condition in drive growth of influenza treatment market.
Influenza treatments include all the anti-viral medications which are employed in the treatment of the influenza. Some of the influenza treatments available in the market include Peramivir, Zanamivir, Oseltamivir Phosphate and others.
Influenza treatment exhibit different mechanism of action on influenza virus. For instance, drugs such as Zanamivir work on influenza by trapping the virus inside the infected cell which prevents the spreading of infection in the respiratory tract.
Loading Table Of Content...
